Original articleChemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia: Reappraisal of epidemiological, clinical, and pathological features
Section snippets
Patients
Patients who presented with intertriginous dermatitis shortly after treatment with a chemotherapeutic agent and were assessed in our dermatology department between January 1, 1999, and September 1, 2009, were analyzed; all patients were from the Instituto Valenciano de Oncologia, an oncology center in Valencia, Spain. The study was approved by the center's ethics committee.
The following clinical data were recorded for each patient: age, sex, location of the lesion, interval between the
Results
A total of 21 patients were evaluated. The clinical data are summarized in Table II. Six male (28%) and 15 female (72%) patients had the intertriginous pattern. The mean patient age was 52 years (range 10-69 years). Clinical findings included pruritus or burning in 14 patients (66%), whereas 7 patients reported no symptoms (34%). The clinical morphology of the cutaneous eruptions included erythematous and desquamative patches, papules, plaques, or vesicles. The distribution was bilateral in all
Discussion
This study, along with data obtained from a previous series published in the literature by Valks et al6 and Prussick,7 establishes the epidemiologic, clinical, and pathological features of a previously poorly described and defined, but specific chemotherapy-related cutaneous side effect. We propose the term “chemotherapy-related bilateral dermatitis associated with eccrine squamous syringometaplasia” (CBDESS) for this distinctive entity.
Recently, the term “toxic erythema of chemotherapy” was
References (34)
- et al.
Toxic erythema of chemotherapy: a useful clinical term
J Am Acad Dermatol
(2008) - et al.
Chemotherapeutic agents and the skin: an update
J Am Acad Dermatol
(2008) - et al.
Eccrine squamous syringometaplasia and cytomegalovirus infection
Rev Med Interne
(2003) - et al.
Imatinib-induced eccrine squamous syringometaplasia
J Am Acad Dermatol
(2006) - et al.
Drug excretion in human eccrine sweat
J Invest Dermatol
(1971) - et al.
Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?
Ann Oncol
(2005) - et al.
Syringometaplasia: mucinous and squamous variants
J Cutan Pathol
(1979) - et al.
Eccrine squamous syringometaplasia: a cutaneous sweat gland reaction in the histologic spectrum of ‘chemotherapy-associated eccrine hidradenitis’ and ‘neutrophilic eccrine hidradenitis’
Arch Dermatol
(1990) - et al.
Eccrine squamous syringometaplasia: a prospective clinicopathologic study
J Cutan Pathol
(1993) - et al.
Eccrine syringosquamous metaplasia
Int J Dermatol
(2001)
Eccrine squamous syringometaplasia secondary to pegylated liposomal doxorubicin
Arch Dermatol
Chemotherapy-induced eccrine squamous syringometaplasia: a distinctive eruption in patients receiving hematopoietic progenitor cells
Arch Dermatol
Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
Semin Cutan Med Surg
Necrotizing eccrine squamous syringometaplasia presenting as acral erythema
J Cutan Pathol
A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature
J Dermatol
Eccrine squamous syringometaplasia from chemotherapy extravasation
Actas Dermo-Sif
Recall phenomenon with the unusual presence of eccrine squamous syringometaplasia
Br J Dermatol
Cited by (41)
Encorafenib-induced eccrine squamous syringometaplasia
2024, Annales de Dermatologie et de VenereologieEccrine squamous syringometaplasia may be associated with previous cryotherapy and photodynamic therapy
2023, Annales de Dermatologie et de VenereologieCutaneous eccrine inflammation and necrosis: review of inflammatory disorders affecting the eccrine apparatus including new associations
2021, Human PathologyCitation Excerpt :The most common type of syringometaplasia is SSM, in which the normal cuboidal cells of eccrine glands are replaced with keratinizing squamous cells with ample eosinophilic cytoplasm [75] (Fig. 11). SSM manifests clinically as erythematous macules, papules, plaques, or vesicles, which may start in the flexures [76]. Lesions can be localized or generalized in distribution and often appear 2–39 days after chemotherapy, then resolve spontaneously.
Cutaneous Adverse Reactions of Anticancer Agents
2019, Dermatologic ClinicsCitation Excerpt :Sites affected were axillae, groin, and sides of neck, in descending order of frequency.26 Resolution occurs in about 2 to 4 weeks with fine desquamation and occasional postinflammatory hyperpigmentation.4,26 Similar to NEH, it is thought that secretion and subsequent concentration of drugs in the eccrine apparatus results in injury.25
Clinical and histopathological spectrum of toxic erythema of chemotherapy in patients who have undergone allogeneic hematopoietic cell transplantation
2019, Hematology/ Oncology and Stem Cell Therapy
Funding sources: None.
Conflicts of interest: None declared.